The 18 most recent market catalysts affecting $ABCL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 55
Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target
Goldman Sachs analyst Andrea Newkirk has reinstated coverage on AbCellera Biologics (ABCL) with a 'Neutral' rating and a $13 price target. This action is significant because a rati…
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 60
AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause
AbCellera has announced an upcoming oral presentation of interim Phase 2 data for its drug candidate ABCL635 at the IMS 20th World Congress on Menopause in October 2026. This is a …
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics (ABCL) experienced a significant stock surge, despite no direct company-specific news. The market is attributing this to the FDA's approval of two cancer treatm…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 75
AbCellera Prices Oversubscribed $200.0M Offering Of 17,435,897 Common Shares At $9.75 Per Share
This headline signifies a significant capital raise for AbCellera, providing them with $200 million for operations, research, and potential acquisitions. While the 'oversubscribed'…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 85
What's Going on With AbCellera Biologics Stock On Wednesday?
AbCellera Biologics (ABCL) shares are trading higher due to the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for menopausal hot flas…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 85
AbCellera Biologics shares are trading lower after the company announced a $200 million offering.
The announcement of a $200 million stock offering by AbCellera Biologics (ABCL) is a significant corporate catalyst. Such offerings increase the number of outstanding shares, dilut…
Aug 11, 2026
Corporate Catalyst
Neutral
Impact 65
AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares
AbCellera Biologics is commencing an underwritten public offering to raise $200 million. This capital raise, while providing funds for research and development, including their lea…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 65
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30
Truist Securities analyst Robyn Kamaus has maintained a 'Buy' rating on AbCellera Biologics (ABCL) and substantially raised the price target from $12 to $30. This significant incre…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 95
AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'
AbCellera Biologics reported compelling Phase 2 results for ABCL635, an investigational neurokinin 3 receptor antagonist for menopause-related hot flashes. The data demonstrated st…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 85
AbCellera Biologics shares are trading higher after the company announced its Phase 2 portion Phase 1/2 clinical trial evaluating ABCL635 met its primary endpoint.
This headline represents a significant positive corporate catalyst for AbCellera Biologics. Meeting a primary endpoint in a Phase 2 clinical trial is a crucial de-risking event for…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 85
AbCellera’s ABCL635 Meets Primary Endpoints In Phase 2 Vasomotor Symptom Study
AbCellera announced that its investigational drug, ABCL635, successfully met primary efficacy endpoints in its Phase 2 clinical trial for moderate-to-severe vasomotor symptoms (hot…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 85
Market-Moving News for August 10th
AbCellera (ABCL) announced highly positive Phase 2 trial results for ABCL635, demonstrating significant symptom reduction and improved sleep. This is a major positive catalyst, as …
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 85
AbCellera Reports Phase 2 Trial Results Showing Significant Symptom Reduction, Improved Sleep, And Favorable Tolerability For ABCL635
AbCellera reported positive Phase 2 results for ABCL635, an investigational drug for moderate-to-severe vasomotor symptoms (hot flashes). The study met its primary efficacy endpoin…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
12 Health Care Stocks Moving In Friday's After-Market Session
This SEC 8-K filing, generated by Benzinga, details the after-market trading activity for a selection of healthcare stocks. The primary catalyst for the positive movement in AbCell…
Aug 7, 2026
Corporate Catalyst
Neutral
Impact 75
AbCellera To Release Top-Line Data From Phase 2 Trial Evaluating ABCL635 For Treatment Of Moderate-To-Severe Vasomotor Symptoms Due To Menopause On August 10
AbCellera (ABCL) has announced it will release top-line data from its Phase 2 trial for ABCL635, a treatment for moderate-to-severe vasomotor symptoms due to menopause, on August 1…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 55
Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9
Stifel analyst Stephen Willey maintained a 'Buy' rating on AbCellera Biologics (ABCL) and raised the price target from $8 to $9. This action signals continued confidence in the com…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 95
AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate
AbCellera Biologics (ABCL) reported a Q2 EPS of $(0.18), missing the $(0.14) estimate by 28.57%, and sales of $4.050 million, missing the $7.784 million estimate by 47.97%. This re…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
AbCellera Announces $28M Upfront Vertex Collaboration On Multispecific T-Cell Engagers For Autoimmune Diseases, Eligible For Milestone Payments And Tiered Royalties
The $28M upfront payment is a direct cash injection for AbCellera, bolstering its balance sheet and validating its drug discovery platform. The potential for milestone payments and…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.